A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis

NCT03119649 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

59

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis

Interventions

DRUG: GLPG2222 50 mg
DRUG: GLPG2222 100 mg
DRUG: Placebo
DRUG: GLPG2222 200 mg
DRUG: GLPG2222 400 mg

Sponsor

Lakefront Biotherapeutics NV